Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

ReCell® spray-on skin system for treating skin loss, scarring and depigmentation after burn injury: a NICE medical technology guidance

Peirce, Susan Caroline ORCID: and Carolan-Rees, Grace 2019. ReCell® spray-on skin system for treating skin loss, scarring and depigmentation after burn injury: a NICE medical technology guidance. Applied Health Economics and Health Policy 17 (2) , pp. 131-141. 10.1007/s40258-018-00457-0

[thumbnail of Re-cell spray-on skin system ....pdf]
PDF - Accepted Post-Print Version
Download (436kB) | Preview


The gold standard treatment for deep burns is an autologous skin graft; in larger burns this may be meshed to increase the area covered. However, long-term aesthetic and functional outcomes of graft scars may be poor. ReCell® is a medical device that processes skin samples in the operating theatre into a cell suspension to be sprayed or dripped onto a wound. It is claimed to improve healing and scar appearance. This device was evaluated by the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme. Two groups were defined: ReCell compared to conventional dressings in shallower burns, and meshed grafts plus ReCell compared to meshed grafts alone in larger deeper burns. The manufacturer’s clinical evidence submission included three papers and eight conference abstracts. The External Assessment Centre (EAC) excluded two of these and added seven abstracts. In general, the evidence did not fit the defined groups, but suggested that ReCell was clinically comparable to skin grafts for partial thickness burns; however, ReCell is not used in this way in the UK. The manufacturer submitted an economic model in which ReCell treatment of partial thickness burns reduced the requirement for later skin grafts. This indicated that ReCell alone was cost saving in comparison to conventional dressings. The EAC indicated that this model was clinically inappropriate, but data were not available to populate a new model. NICE Medical Technologies Guidance 21 recommended that additional research was needed to address the uncertainties regarding the potential benefits of ReCell.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Engineering
Publisher: Adis / Springer Verlag (Germany)
ISSN: 1175-5652
Date of First Compliant Deposit: 22 January 2019
Date of Acceptance: 4 December 2018
Last Modified: 25 Oct 2022 12:07

Citation Data

Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics